Therapeutic approaches aimed at M2 macrophages in AML include blocking the recruitment of CCR2+CD14++ CD16- (TAM precursors), the inhibition of CCL2-CCR2 signaling pathways, and reprogramming M1-like macrophages in terms of their function and phenotype [115]. The gene discussed is CCR2; the disease is acute myeloid leukemia.